Biden announces willingness to forcibly license pharma patents
But the US administration’s proposed policy for compulsory licensing is somewhat less radical than the rhetoric suggests
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.